Tirzepatide

What is Tirzepatide?

Tirzepatide is a once-weekly injectable peptide pharmaceutical that activates both glucose-dependent insulinotropic polypeptide receptors and glucagon-like peptide-1 receptors. The practical effects are reduced appetite, improved glucose-dependent insulin secretion, altered glucagon signaling, delayed gastric emptying, and lower body weight. In the pivotal obesity program, Jastreboff 2022 showed substantial weight reduction versus placebo in adults with obesity or overweight without diabetes. In type 2 diabetes, Frias 2021 showed greater glycemic and weight effects than semaglutide 1 mg.

From the BioHarmony report, reviewed 2026-09-19.

Safety watch-outs

• Persistent vomiting or dehydration
• Severe abdominal pain
• Blood in stool or black stool
• Symptoms of pancreatitis: severe upper abdominal pain radiating to back
• Right upper quadrant pain, fever, jaundice, or pale stools (gallbladder)

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for Tirzepatide yet.

Related peptides for weight & metabolic

1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
3. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…
4. 6.0/10SS-31 (Elamipretide)Worth tryingRecoveryFDA-approved product existsSS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin.